This company has been acquired
Chimerix (CMRX) Stock Overview
A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CMRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Chimerix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.54 |
| 52 Week High | US$8.55 |
| 52 Week Low | US$0.75 |
| Beta | -0.18 |
| 1 Month Change | 0.47% |
| 3 Month Change | 125.93% |
| 1 Year Change | 822.94% |
| 3 Year Change | 81.32% |
| 5 Year Change | 465.56% |
| Change since IPO | -54.55% |
Recent News & Updates
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
Feb 20Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Dec 11Recent updates
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
Feb 20Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Dec 11We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate
Jul 16
Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation
Aug 23Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Jul 20Chimerix: Down But Not Out
Jun 06Chimerix: Searching For Clarity
Jan 05Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Dec 24Is Chimerix (NASDAQ:CMRX) A Risky Investment?
Sep 16Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Jun 08Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?
May 13Shareholder Returns
| CMRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.1% | -1.7% | -2.0% |
| 1Y | 822.9% | 24.5% | 14.4% |
Return vs Industry: CMRX exceeded the US Biotechs industry which returned -7.1% over the past year.
Return vs Market: CMRX exceeded the US Market which returned 2.5% over the past year.
Price Volatility
| CMRX volatility | |
|---|---|
| CMRX Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CMRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CMRX's weekly volatility has decreased from 34% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 79 | Mike Andriole | www.chimerix.com |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. The company also develops ONC212, an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trial; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses.
Chimerix, Inc. Fundamentals Summary
| CMRX fundamental statistics | |
|---|---|
| Market cap | US$801.08m |
| Earnings (TTM) | -US$88.39m |
| Revenue (TTM) | US$212.00k |
Is CMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMRX income statement (TTM) | |
|---|---|
| Revenue | US$212.00k |
| Cost of Revenue | US$74.57m |
| Gross Profit | -US$74.36m |
| Other Expenses | US$14.03m |
| Earnings | -US$88.39m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | -35,076.42% |
| Net Profit Margin | -41,691.98% |
| Debt/Equity Ratio | 0% |
How did CMRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/22 19:36 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chimerix, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | Barclays |
| Ritu Baral | Canaccord Genuity |
| Daniel Brims | Cantor Fitzgerald & Co. |